FP

Formosa Pharmaceuticals and Singapore Eye Research Institute (SERI) Partner to Advance Novel Ophthalmic Formulations for Corneal Diseases

News / By

Formosa Pharmaceuticals and Singapore Eye Research Institute (SERI) Partner to Advance Novel Ophthalmic Formulations for Corneal Diseases SINGAPORE / TAIPEI — April 30, 2026 – Formosa Pharmaceuticals, Inc. (“Formosa”, 6838.TW) and the Singapore Eye Research Institute (“SERI”) are pleased to announce a strategic research collaboration to develop next-generation ophthalmic formulations. This partnership will leverage Formosa’s …

Formosa Pharmaceuticals and Singapore Eye Research Institute (SERI) Partner to Advance Novel Ophthalmic Formulations for Corneal Diseases Read More »

Advancing Women’s Football Professionalization! Formosa Pharmaceuticals Supports Taipei Bravo’s Japan Exchange to Deepen International ESG Commitments

ESG / By

2026/4/20 To further its ESG sustainability initiatives and foster social prosperity, Formosa Pharmaceuticals supported the Taipei Bravo Women’s Football Team during their visit to sister club Viamaterras Miyazaki in Japan on April 18 and 19. The two-day international exchange included joint training sessions to refine technical skills and an invitation to attend a Viamaterras first-team …

Advancing Women’s Football Professionalization! Formosa Pharmaceuticals Supports Taipei Bravo’s Japan Exchange to Deepen International ESG Commitments Read More »

See the Power in the Small: Formosa Pharmaceuticals Supports Taipei Bravo Women’s Football in Spirited 2026 WBC Cheer Campaign, Fulfilling ESG Health Commitments

ESG / By

3/3/2025 As the 2026 World Baseball Classic (WBC) kicks off, a new wave of baseball fever is sweeping across Taiwan. Last night, the “Taipei Bravo Women’s Football Team,” sponsored by Formosa Pharmaceuticals (6838), joined several of the nation’s top athletic teams to offer their heartfelt support and blessings to Team Taiwan (Chinese Taipei) as they …

See the Power in the Small: Formosa Pharmaceuticals Supports Taipei Bravo Women’s Football in Spirited 2026 WBC Cheer Campaign, Fulfilling ESG Health Commitments Read More »

Formosa Pharmaceuticals Announces Licensing Agreement with Arrotex, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery

News / By

Formosa Pharmaceuticals Announces Licensing Agreement with Arrotex, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery TAIPEI – February 23, 2026 – Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Arrotex Pharmaceuticals Pty Ltd. (“Arrotex”), for exclusive …

Formosa Pharmaceuticals Announces Licensing Agreement with Arrotex, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery Read More »

Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery

News, Uncategorized / By

Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery TAIPEI – January 12, 2026 – Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Samil Pharmaceuticals, Co., Ltd …

Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery Read More »

Formosa Pharmaceuticals Announces Licensing Agreement with Rxilient, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery

News / By

Formosa Pharmaceuticals Announces Licensing Agreement with Rxilient, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery TAIPEI – December 3, 2025 – Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838.TW) announced today that the company has entered into an exclusive licensing agreement  with Rxilient Medical Pte. Ltd. (“Rxilient”), for exclusive …

Formosa Pharmaceuticals Announces Licensing Agreement with Rxilient, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery Read More »

Safeguarding Our Oceans: Formosa Pharmaceuticals Champions Sustainability through Tamsui Beach Clean-up

ESG / By

11/14/2025 Formosa Pharmaceuticals, Inc. spent a meaningful day today at the shoreline of Tamsui, New Taipei City, where our team members joined forces to clean up the coast and protect our precious marine environment. This beach clean-up initiative is a core component of our ongoing commitment to ESG (Environmental, Social, and Governance) and environmental sustainability. …

Safeguarding Our Oceans: Formosa Pharmaceuticals Champions Sustainability through Tamsui Beach Clean-up Read More »

ESG in Action: Formosa Pharmaceuticals Backs the Alliance’s Five Key Actions

ESG / By

10/08/2025 Formosa Pharmaceuticals announced its participation in the inaugural advocacy conference of the “Vision-Friendly Alliance,” initiated by Dialogue in the Dark (DiD) Social Enterprise, held on the eve of World Sight Day (October 8). Joining hands with partners across industry, government, academia, and social welfare, the company aims to advance a more inclusive and accessible …

ESG in Action: Formosa Pharmaceuticals Backs the Alliance’s Five Key Actions Read More »

Harrow Acquires U.S. Commercial Rights to BYQLOVI (Clobetasol Propionate Ophthalmic Nanosuspension) 0.05% from Formosa Pharmaceuticals

News / By

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals NASHVILLE, Tenn. and Taipei, Taiwan, June 9, 2025 – Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838.TW), today announced a licensing agreement, whereby Harrow has acquired the exclusive U.S. commercial rights for …

Harrow Acquires U.S. Commercial Rights to BYQLOVI (Clobetasol Propionate Ophthalmic Nanosuspension) 0.05% from Formosa Pharmaceuticals Read More »

Formosa Pharmaceuticals and Adalvo Limited Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain

News / By

Formosa Pharmaceuticals and Adalvo Limited Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain TAIPEI – May 28, 2025 – Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838.TW) announced that the company has entered into an exclusive licensing agreement with Adalvo Limited (“Adalvo”) in the European and Brazilian markets for exclusive …

Formosa Pharmaceuticals and Adalvo Limited Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Read More »

Scroll to Top